Literature DB >> 36263107

Prognostic Value of Short-Term Follow-up of Multiple Biomarkers After Discharge in Hospitalized Patients With Acute Heart Failure (POSTBIO-HF): Rationale and Study Design.

Dong-Hyuk Cho1, Jung-Woo Son1, Chan Joo Lee2, Jimi Choi3, Mi-Na Kim4, Ju-Hee Lee5, Sunki Lee6, Dong Heon Yang7, Hyun-Jai Cho8, Jin-Oh Choi9, Eung Ju Kim10, Dong-Ju Choi11, Byung-Su Yoo1.   

Abstract

Several surrogate biomarkers possess prognostic significance for heart failure (HF), and a decline in their respective values may predict clinical improvement. However, data on the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated HF are scarce. We aim to evaluate the prognostic value of short-term follow-up of surrogate biomarkers for predicting the prognosis of hospitalized patients with acute decompensated HF. This multi-center, prospective study will enroll consecutive hospitalized patients with acute decompensated HF. All patients will undergo sampling and comparison of biomarkers, including plasma N-terminal pro-brain natriuretic peptide, growth differentiation factor 15, troponin-T, high-sensitivity C-reactive protein, and urinary albumin/creatinine ratio obtained within 1 month and 6 months after discharge from the index admission. The primary endpoint is a composite of cardiovascular mortality or HF hospitalization during 1 year of follow-up. We will investigate the prognostic value of multiple biomarkers for the primary endpoint. This trial will provide robust evidence for novel multi-biomarker strategies for acute decompensated HF in real-world settings. Trial Registration: ClinicalTrials.gov Identifier: NCT04437628.
Copyright © 2022. Korean Society of Heart Failure.

Entities:  

Keywords:  Biomarkers; Heart failure

Year:  2022        PMID: 36263107      PMCID: PMC9383348          DOI: 10.36628/ijhf.2022.0005

Source DB:  PubMed          Journal:  Int J Heart Fail        ISSN: 2636-154X


  18 in total

1.  Multiple biomarkers for risk prediction in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Wayne C Levy; Nancy K Sweitzer; James C Fang; Alan H B Wu; Lee R Goldberg; Mariell Jessup; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2012-02-23       Impact factor: 8.790

2.  On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.

Authors:  Hajime Uno; Tianxi Cai; Michael J Pencina; Ralph B D'Agostino; L J Wei
Journal:  Stat Med       Date:  2011-01-13       Impact factor: 2.373

3.  B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

Authors:  Peder Langeland Myhre; Muthiah Vaduganathan; Brian Claggett; Milton Packer; Akshay S Desai; Jean L Rouleau; Michael R Zile; Karl Swedberg; Martin Lefkowitz; Victor Shi; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2019-03-04       Impact factor: 24.094

4.  A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.

Authors:  Biniyam G Demissei; Gad Cotter; Margaret F Prescott; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Peter S Pang; Piotr Ponikowski; Thomas M Severin; Yi Wang; Min Qian; John R Teerlink; Marco Metra; Beth A Davison; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2017-01-30       Impact factor: 15.534

5.  Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry).

Authors:  Jin Joo Park; Dong-Ju Choi; Chang-Hwan Yoon; Il-Young Oh; Eun-Seok Jeon; Jae-Joong Kim; Myeong-Chan Cho; Shung Chull Chae; Kyu-Hyung Ryu; Byung-Su Yoo; Seok-Min Kang; Byung-Hee Oh
Journal:  Am J Cardiol       Date:  2013-11-09       Impact factor: 2.778

6.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

Authors:  V Cheng; R Kazanagra; A Garcia; L Lenert; P Krishnaswamy; N Gardetto; P Clopton; A Maisel
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

7.  Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

Authors:  Inder S Anand; Tibor Kempf; Thomas S Rector; Heike Tapken; Tim Allhoff; Franziska Jantzen; Michael Kuskowski; Jay N Cohn; Helmut Drexler; Kai C Wollert
Journal:  Circulation       Date:  2010-09-20       Impact factor: 29.690

8.  Cardiac troponin and outcome in acute heart failure.

Authors:  W Frank Peacock; Teresa De Marco; Gregg C Fonarow; Deborah Diercks; Janet Wynne; Fred S Apple; Alan H B Wu
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

9.  Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.

Authors:  Nadia Bouabdallaoui; Brian Claggett; Michael R Zile; John J V McMurray; Eileen O'Meara; Milton Packer; Margarett F Prescott; Karl Swedberg; Scott D Solomon; Jean L Rouleau
Journal:  Eur J Heart Fail       Date:  2018-09-11       Impact factor: 15.534

10.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.